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Abstract: Wild berries are part of traditional Nordic diets and are a rich source of phytochemicals,
such as polyphenols. Various berry treatments have shown to interfere with cancer progression
in vitro and in vivo. Here, we systematically reviewed the anticancer effects of two Nordic wild
berries of the Vaccinium genus, lingonberry (Vaccinium vitis-idaea) and bilberry (Vaccinium myrtillus),
on digestive tract cancers. The review was conducted according to the PRISMA 2020 guidelines.
Searches included four databases: PubMed, Scopus, Web of Science, and CAB abstracts. Publications
not written in English, case-reports, reviews, and conference abstracts were excluded. Moreover,
studies with only indirect markers of cancer risk or studies with single compounds not derived from
lingonberry or bilberry were not included. Meta-analysis was not performed. The majority (21/26)
of studies investigated bilberry and colorectal cancer. Experimental studies on colorectal cancer
indicated that bilberry inhibited intestinal tumor formation and cancer cell growth. One uncontrolled
pilot human study supported the inhibitory potential of bilberry on colorectal cancer cell proliferation.
Data from all 10 lingonberry studies suggests potent inhibition of cancer cell growth and tumor
formation. In conclusion, in vitro and animal models support the antiproliferative and antitumor
effects of various bilberry and lingonberry preparations on digestive tract cancers.
Keywords: lingonberry; bilberry; colorectal cancer; oral cancer; proliferation; invasion; migration;
tumorigenesis; phytochemical; polyphenol; anthocyanin; proanthocyanidin
1. Introduction
Diets rich in non-starchy vegetables and fruits reduce the risk of many non-communicable
diseases, such as digestive tract cancers [1,2]. Plant-based diets provide vitamins, miner-
als, and dietary fiber, but also various plant metabolites generally called phytochemicals,
such as polyphenols and phenolic acids. These are food constituents not regarded as
essential but recently shown to have health benefits, especially in the prevention and
management of chronic diseases, including cancer [3,4]. Dietary plants contain thousands
of different phytochemicals, which produce a variety of metabolites in the human digestive
system [4]. Polyphenols can modulate carcinogenic processes, such as cellular proliferation,
differentiation, apoptosis, inflammation, angiogenesis, and metastasis [3,5]. The antho-
cyanins especially raise interest as promising candidates for cancer prevention and drug
development, yet evidence from human trials is still lacking [6].
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Bioavailability of dietary polyphenols and other phytochemicals has been considered
low, since only small concentrations can generally be found in systemic circulation follow-
ing ingestion [4]. However, since dietary phytochemicals are extensively modified by host
and microbial enzymes [4,7], post-prandial serum concentration of a certain phytochemical
is not directly indicative of its biological impact, especially on the digestive tract tissues.
Some phytochemicals are absorbed intact or as degradation products from the upper diges-
tive tract, whereas others travel to lower digestive tract and produce absorbable metabolites
hours later [4,7]. Absorbed compounds are further metabolized in the epithelial cells of
the gastrointestinal wall and liver, after which these metabolites can continue to systemic
circulation or return to the gut lumen due to enterohepatic circulation. Post-prandial
serum concentration of a degradation product can be hundred-fold compared to that of the
original phytochemical ingested [8]. In addition, phenolic compounds can accumulate into
tissues over time [9,10].
Whole berry extracts and berry polyphenols purified from extracts, reduce tumor
cell proliferation in vitro, and reduce tumor formation and growth in murine models [11].
Berry polyphenols not only exerts antioxidant potential but also inhibits inflammation,
invasion, mutagenesis, and induces apoptosis in malignant cells. Some polyphenols inhibit
glucose transport [12] and may therefore inhibit vigorously proliferating tumor cells that
rely on high influx and metabolism of glucose [13].
Lingonberry (Vaccinium vitis-idaea) and bilberry (Vaccinium myrtillus) are common
dietary fruits and one of the richest dietary sources of polyphenols, especially anthocyanins,
in Finnish diets [14,15]. These berries belong to the genus Vaccinium but differ in their
biochemical composition, with the proportion of anthocyanins being considerably high in
bilberry and that of proanthocyanidins in lingonberry [16]. The objective of this systematic
review was to collect current English-written scientific research on the anticancer effects of
lingonberry and bilberry on digestive tract cancers. These effects of berries on digestive
tract cancers have been extensively reviewed by Bishayee et al. [11], but to our knowledge,
no systematic review encompassing anticancer effects of lingonberry or bilberry has been
published to date.
2. Materials and Methods
Protocol of this review was registered and is available in PROSPERO (PROSPERO
2020CRD42020181924). Eligible studies included original research papers with the follow-
ing components: 1. Lingonberry or bilberry treatment (fermented or not fermented whole
berry or berry juice, whole berry extracts, anthocyanin-rich extracts, and other fractions of
extracts derived from bilberry or lingonberry); 2. digestive tract human cancer cell line,
animal model, or human patients; 3. treatment tested on a direct cancer-relevant endpoint,
including the number and size of tumors or pre-cancerous lesions, inhibition of tumor cell
proliferation, cytotoxicity, induction of apoptosis, or invasion and migration of tumor cells.
Publications not written in English, case-reports, reviews, and conference abstracts
were excluded. Studies with only indirect markers of cancer risk, such as oxidative stress or
inflammation, or studies with single compounds not derived from lingonberry or bilberry,
were considered outside the scope of this review.
The literature search was carried out by 2 independent reviewers (TO and AK) on
20.4.2020 and updated on 4.3.2021 in four databases: PubMed, Scopus, Web of Science,
and CAB abstracts. Search syntax for PubMed, Web of Science, and CAB was as follows:
((lingonberr* OR Vaccinium vitis-idaea OR cowberr* OR mountain cranberr* OR bilberr*
OR vaccinium myrtillus OR whortleberr* OR european blueberr*) AND (neoplas* OR
metasta* OR invas* OR migrati* OR malignan* OR polyp* OR aberrant crypt foci OR
adeno* OR tumor* OR onco* OR cancer* OR carcino* OR *cancer OR mutage*)) In Scopus
search was divided into two searches; bilberry: TITLE-Abs KEY ((bilberr* OR myrtillus OR
whortleberr*) AND (neoplas* OR metasta* OR invas* OR migrati* OR malignan* OR polyp*
OR “aberrant crypt foci” OR adeno* OR tumor* OR onco* OR cancer* OR carcino* OR
*cancer OR mutage*)) and lingonberry: TITLE-ABS-KEY ((lingonberr* OR vitis-idaea OR
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cowberr* OR “mountain cranberr*”) AND (neoplas* OR metasta* OR invas* OR migrati*
OR malignan* OR polyp* OR “aberrant crypt foci” OR adeno* OR tumor* OR onco* OR
cancer* OR carcino* OR *cancer OR mutage*)).
Duplicates were removed and titles and abstracts were screened by two independent
reviewers (TO and AK). Full texts were retrieved for included studies and for papers that
did not provide all relevant information in the abstract. A final selection was made in
duplicate based on the full text.
Data from each included study was extracted by 2 independent reviewers (TO and
AK/MM) using a piloted form. Each study was extracted in duplicate. Disagreements
were solved with the 3rd reviewer (AK/MM). Data collected from each study included
publication information, authors, cell line/animal model/human population and site of
cancer, berry species, berry preparation used for exposure, time of exposure, concentration,
end points studied, methods used, controls, number of repeats and replicates (cell studies)
or number of studied individuals (animals or human subjects), results, conclusions made
by authors, reviewers’ evaluation of study quality, and other comments. Due to variable
methodology across studies, collected data was considered suitable for qualitative synthesis
only. Data was tabulated by cancer type (colorectal or oral cancer) and study type (human
study, animal study, or in vitro study).
3. Results
The selection process of the systematic search and numbers of included and excluded
papers are presented in Figure 1. In total, 43 full text articles were assessed for eligibility, of
which 17 [17–33] were excluded based on reasons given in Figure 1. At the end of the selec-
tion process, 26 articles were considered eligible for this review. Of these studies, a great
majority (25/26) investigated colorectal cancer (CRC); only one cell culture study related
to oral cancer was identified, and no publications on other digestive tract cancers with a
lingonberry or bilberry treatment were found. Anticancer effects of bilberry preparations
on CRC were studied in one human clinical study, 7 animal studies, and 13 cell culture
studies. Lingonberry treatment was tested on CRC models in one animal study and 8 cell
culture studies. Study characteristics and main results from animal studies related to CRC
are presented in Table 1 and from cell culture studies in Table 2.
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3.1. Human Study on Colorectal Cancer
To our knowledge, only one clinical pilot human study on bilberry or lingonberry and
any digestive tract cancer has been published to date. Thomasset et al. treated CRC patients
with standardized bilberry anthocyanin rich extract, Mirtocyan (Indena S.p.A., Milan,
Italy), for seven days before scheduled resection of primary tumor or liver metastasis [10].
Patients were randomized into three groups based on dosage (1.4/2.8/5.6 g/day), but
no control group was included. Cellular proliferation and apoptotic index in the tumor
tissue were compared to pre-intervention values. After the one-week treatment, tumor
cellular proliferation decreased by 7% and apoptotic index increased from 3.6% to 5.3% in
all groups combined.
3.2. Animal Studies on Colorectal Cancer
Animal experiments on CRC are presented in Table 1. Animal models used were ge-
netic ApcMin/+ mouse model [9,34,35], toxin-induced carcinogenesis in a rat or mouse [34,35],
and a xenograft mouse model with subcutaneously inoculated human adenocarcinoma
cells [36,37]. Treatments included freeze-dried lingonberry and bilberry [38], as well as
anthocyanin-rich bilberry extracts [9,34–37,39]. All these treatments reduced number
and/or size of intestinal tumors or pre-malignant lesions. However, bilberry extract alone
did not have an effect on subcutaneous tumors in the mouse xenograft, but reduced tumor
volume when given in combination with an immune checkpoint inhibitor drug [36,37].
In the rat model of toxin-induced carcinogenesis, bilberry anthocyanin rich extract
supplementation significantly reduced the number of total and large colonic aberrant crypt
foci (ACF) after 14 weeks of treatment [34]. Proliferation of colonic cells reduced by nearly
50% and rats fed with this extract had reduced expression of COX-2 mRNA, together with a
reduced number of ACF. In a corresponding mouse model study, bilberry anthocyanin rich
extract supplementation for 10 weeks significantly reduced the size and number of colon
tumors [35]. Interestingly, animals fed with 10% of this extract had almost no detectable
tumors at the end of the trial. Reduction in colon length was measured as an indicator of
inflammation and was attenuated together with tumor formation and growth by bilberry
treatment.
Bilberry anthocyanin rich extract was effective also in the genetic ApcMin/+ mouse
model, reducing dose-dependently the number of small intestinal adenomas [9]. In another
study using this mouse model, freeze dried bilberry reduced only the number, but inter-
estingly not the size of adenomas [38]. Similarly, the number of tumors was reduced by
bilberry anthocyanins in ApcMin/+ mice treated with antibiotics and subsequently infected
with enterotoxigenic Bacteroides fragilis, but tumor size was not reported in this study [39].
Freeze dried lingonberry, however, reduced both the number and size of intestinal adeno-
mas [38]. This was the only animal study conducted with a lingonberry treatment and the
only study with a whole-berry preparation instead of an anthocyanin rich extract.
In the two studies on a mouse xenograft with subcutaneous CRC tumors, bilberry
anthocyanin rich extract alone did not affect tumor volume but enhanced the effectivity
of an immune checkpoint inhibitor drug in combination therapy [36,37]. Enhancement
of tumor control was associated with tumor immune filtration in the study of Liu et al.,
and was abolished with antibiotic treatment in Wang et al. publication, suggesting a role
for modulation of gut microbiota and/or immune responses by bilberry anthocyanin rich
extract [36,37].
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Table 1. Colorectal cancer: Main results of animal studies.
Publication Berry Population/Model Endpoint Method Treatment Effect
Lala et al., 2006 [34]
(a) Bilberry
Fisher 344 male rats
treated with
azoxymethane
n = 10 per group
1. Number and
multiplicity of colonic
aberrant crypt foci (ACF)
2. Colonic cell
proliferation









ARE/kg for 14 weeks
1. Significantly reduced number
of total and large ACF compared
to control. Number of large ACF
was reduced by 70%
2. Significantly decreased colonic
cellular proliferation by nearly
50%
Cooke et al., 2006 [9]
(b) Bilberry
ApcMin/+ mice
n = 16 per group
Number, location, and




Standard diet with ARE
from bilberry
(Mirtoselect): Group 1:
0.03%, Group 2: 0.1%,
Group 3: 0.3%




adenoma load compared to
control (number reduced by 30%
with highest dose). Reduced










n = 10–12 in group
Sum of adenoma areas Dissection aftertermination
10% w/w freeze-dried
bilberry or lingonberry
in High-fat AIN93 diet
for 10 weeks
Both berries significantly
inhibited number of adenomas by
15–30% compared to control.
Bilberry did not reduce the size of
adenomas, but lingonberry
reduced adenoma burden by 60%













at weeks 4 and 9,
macroscopic and
microscopic analysis




1% or 10% w/w of extract
in diet for 10 weeks
Significantly smaller and less
(almost no detectable tumors) in
10% ARE fed mice compared to
controls or mice fed with 1%
extract. Smaller and less tumors
also with 1% extract compared to
control, but difference not
statistically significant
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Table 1. Cont.
Publication Berry Population/Model Endpoint Method Treatment Effect







n = 6 per group
Tumor number Dissection aftertermination
Bilberry anthocyanin
extract
on average 8.6 mg/kg
body weight by gavage 3
times a week for 4 weeks
Significantly reduced tumor
number
approx. 50% compared to control
















156 ug of anthocyanins
daily
for 27 days
Extract alone did not affect tumor
volume compared to control, but
significantly enhanced the effect
of the drug, possibly through
modulation of gut microbiota
(effect was abolished by antibiotic
treatment)



















daily for 2 weeks
Extract was not tested alone but
enhanced therapeutic effects of
the drug. Enhanced tumor
immune filtration was associated
with improvement of tumor
control.
Animal model type used: (a) induced carcinogenesis, (b) genetic model, and (c) xenograft.
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In these reviewed animal studies, formation and growth of intestinal tumors or
pre-cancerous lesions was inhibited with 10% (w/w) of freeze-bilberry or lingonberry in
diet [38], from a few grams/kg to 10% (w/w) of bilberry anthocyanin extract in diet [9,35],
and with 3.85 g of bilberry anthocyanin rich extract/kg in diet [34]. When administered
separately, 8.6 mg/kg of bilberry anthocyanin extract 3 times per week reduced tumor
number by approximately 50% compared to the control [39]. In the studies on xenograft
models, 156 µg/day per mouse and 25 mg/kg body weight daily of bilberry anthocyanin
extract were sufficient for enhancing a therapeutic effect of an immune checkpoint inhibitor
drug [36,37].
3.3. In Vitro Studies on Colorectal Cancer
Studies on CRC cell lines are presented in Table 2. A total of 10 studies with a bilberry
treatment, 5 with a lingonberry treatment, and 3 with both were identified. In these
studies, berry extracts were found to reduce CRC cell proliferation [39–51] and induce
apoptosis [44,49,52]. Furthermore, tumor cells were more sensitive than non-tumorigenic
cells to the anti-proliferative effects of investigated berry extracts [39,43].
The inhibition of cell proliferation was most commonly measured, and various bilberry
extracts were effective in all studies in which their effect on the growth of CRC cells were
analyzed [39,41,43–45,47–51]. Similarly, various lingonberry extracts inhibited proliferation
in all studies which tested lingonberry extracts on CRC cell proliferation [40–42,44,46].
Within individual studies, higher concentrations of various berry extracts and longer expo-
sure times generally led to higher inhibition of tumor cells, but similar consistency could
not be seen when results of all studies were compared, possibly due to different chemical
compositions of tested extracts. Only two studies compared inhibition of tumor cells to
that of non-tumorigenic digestive tract cells, both indicating greater sensitivity of tumor
cells [39,43]. Zhao et al. (2004) found that tumor cells responded to bilberry extract at lower
concentrations (25µg of monomeric anthocyanin/mL) and at earlier timepoints (48 and
72 h) compared to non-tumorigenic cells, with significant growth inhibition of 24% and 53%,
respectively [43]. Time-dependent inhibition was observed with higher concentrations (50
and 75 of monomeric anthocyanin/mL), whereas non-tumorigenic immortalized NCM460
cells were significantly inhibited only after 72 h with all concentrations. Similarly, in the
study of Mudd et al. (2020), non-tumorigenic colon cells were less sensitive than tumor cells
to bilberry anthocyanins, with IC50 values of 124 and 75 µmol/mL for tumorigenic HT-29
and HCT116, respectively, and 1050 µmol/mL for non-tumorigenic NCM460 cells [39].
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Table 2. Colorectal cancer: Main results of in vitro studies.












2. DNA extraction and
agarose gel electrophore-
sis/Analysis of nuclear
morphology by 1 mM
bisbenzimide staining
1. 2–4 mg dry weight/mL of
bilberry/lingonberry ethanol extract for
48 h, in addition bilberry ethanol
extract for 24 and 48 h with 0.5–4 mg
dry weight/mL
2. 4 mg/mL bilberry extract for 24 h
1. Bilberry and lingonberry ethanol extracts
strongly inhibited the growth of HCT116.
Bilberry inhibited cell growth >50% with
2–4 mg/mL. Over 50% inhibition was
achieved also with 4 mg/mL lingonberry
extract
2. Bilberry extract did not induce apoptosis
Olsson et al.,





0.025–0.5% of plant dry matter of total
weight in the wells
for 24 h
Decreased proliferation significantly and
dose-dependently. GI50 between 0.25% and
0.5% of plant dry matter in the wells

















inhibited growth of HT-29 with 50–75
µg/mL of monomeric anthocyanin from 24
h on, with 25 µg/mL from 48 h on. Over
50% inhibition for all concentrations after
72 h.


















2. 5–60 mg/mL bilberry extract
for 48 h
1. Both inhibited cell growth significantly.
Bilberry
GI50 = approx. 15 mg/mL
Lingonberry
GI50 = 60 mg/mL
2. Bilberry induced apoptosis with 20–60
mg/mL
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Table 2. Cont.
Study Berry Cell Line Endpoints Methods Exposure Effect
Jing et al.,








equivalents for 48 h
Dose-dependent inhibitory effect on the
growth of HT29.




Lingonberry Caco-2 Cell growthinhibition Dojindo CCK-8 kit
Lingonberry acetonitrile extract
(bound fraction from solid phase
extraction only) 25–75 µg of gallic acid
equivalents/mL for 72 h
Inhibited cell growth in a dose-dependent










Bilberry extract from European bilberry
pomace (Kaden Biochemicals,
Hamburg, Germany)
1. 5–500 µg/mL for 1 and 24 h
2. 0.01–500 µg/mL for 1 and 24 h
1.Significant effect only on HT-29, with 500
µg/mL only. EC50 was not reached
2. Decreased induced DNA damage only in
Caco-2 cells, with 5–100 µg/ml
Esselen et al.,















Bilberry industrial ARE (Indena, Milan,
Italy)
1. 50–500 µg/mL for 72 h
2. 1–0 µg/mL for 1 h
3. 0.01–50 µg/mL, 30 min pre + 1 h
coincubation
1. Bilberry ARE inhibited HT29 growth
dose-dependently. GI50 was not reached
2. Bilberry ARE increased the rate of DNA
strand brakes, but no additional oxidative
damage observed
3.DNA-damaging effects and cytotoxicity
of both drugs were inhibited by bilberry
ARE
Fan et al.,






Proliferation significantly inhibited in a
dose-dependent manner, GI50 approx. 35
mg/mL
Kropat et al.,










Inhibited cell growth significantly, with
concentrations above 100 µg/mL. GI50
between 200 and 400 µg/mL
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Table 2. Cont.











2. Cell Death Detection
ELISAPLUS Assay with
BCA protein assay
Bilberry extract, raw juice and press
residue extracts obtained from
extraction in different temperatures
(40/60/80/100 C)
1. 30 min exposure to 75–250 mg GAE/l.
Measurement after 24 h
2. 24-h exposure with 75–250 mg
GAE/l of press residue extracts
1. All extracts inhibited proliferation of all
cell lines. Dose-response inhibition of all
extracts on all cell lines, except for raw juice
on HT-29 and HCT 116. GI50 of Caco-2 and
HCT 116 was reached with all extracts, of
HT-29 only press residue extracts from
80–100 ◦C temperatures
2. Dose response for both tested press












2. Matrigel invasion and
migration assays
Lingonberry methanol extract prepared
to:
IVDL: In vitro digested extract and
IVFL: In vitro fermented extract
both 3–50 µg/mL GAE for 24 h
Ileal fluid after lingonberry ingestion,
3–200 µg/mL for 24 h
1. No cytotoxic activity for any exposure





Bilberry LS147 Cell viability MTT assay




Both teas decreased viability
Decoction tea EC50: 176.32 µg/mL









Fraction 1: Polar substances
Fraction 2: 6 flavonols detected
Fraction3: 8 phenolic acids identified
62.5–1000 µg of dried fraction/mL
for 48 h
Fractions 2 and 3 suppressed cell growth
significantly and dose-dependently. Over
50% growth inhibition achieved with ≥125
µg/mL of fraction 2, and with ≥500 µg/mL
of fraction 3. Fraction 1 resulted in less than
10% inhibition with 250–500 µg/mL.
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Table 2. Cont.


















5–75 µg/mL of each fraction
during seeding and for 24 h for SW620
and 48 h for SW480
Bilberry induced apoptosis via extrinsic
pathway
EC50 for bilberry treated SW620: 24.7
µg/mL and SW480: 25.2 µg/mL












Bilberry juice extract (no solvent used)
1. 12.5–400 µg dry mass/mL
for 48 h
2. 100 µg dry mass/mL 48 h
1. Viability of Caco-2 was significantly but












MTT assay Bilberry anthocyanin extractconcentrations up to 200 µmol/L
Bilberry anthocyanin extract inhibited
proliferation of tumor cells more than colon
cells






Lingonberry HT-29 Cell viability MTT assay
Lingonberry extracted in acetone and
phenolic fractions subsequently isolated
with column chromatography
Lingonberry extract fractions reduced
viability with EC50 values approx. 0.05–1.1
mg/mL, Fraction 4 rich in
proanthocyanidins being the most effective
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Some in vitro studies reported cytotoxicity or cell viability instead of inhibition of
proliferation, with inconsistent results [47,52–54,56]. Mild toxicity was reached with
400 ug/mL of bilberry juice on Caco-2 [56] and with 500 ug/mL of bilberry pomace extract
on HT-29 CRC cells [52]. Bilberry decoction and infusion teas were cytotoxic to LS147 CRC
cells with approximately 180 ug/mL EC50 values [54]. However, no toxicity was detected
for 4 mg/mL of bilberry extract on HCT116 [41], or for in vitro digested or fermented
lingonberry extracts on HT-29 or HT115 with concentrations below 50 ug/mL [53]. On
the other hand, bilberry reduced toxicity of topoisomerase poisons in the study of Esselen
et al., raising the possibility of counteracting therapeutic toxicity of chemotherapy [47].
Induction of apoptosis in CRC cells was also investigated [41,44,49,52]. Bilberry
extracts induced apoptosis in HT-29 cells with concentrations above 20 mg/mL [44,49]
but not in HCT116 with a concentration of 4 mg/mL [41]. Proanthocyanin-rich extracts of
both lingonberry and bilberry induced apoptosis in SW820 and SW640 cells with much
lower concentrations; EC50s for both extracts were below 25 ug/mL [55]. Apoptosis was
further investigated in this study with bilberry proanthocyanidin extract and was found to
be induced via the extrinsic pathway.
3.4. Oral Cancer
No eligible in vivo studies on lingonberry or bilberry and oral cancer were found,
but one eligible study on oral carcinoma cells was identified (Table 3). Hoornstra et al.
(2018) found that lingonberry juice fermented using Saccharomyces cerevisiae inhibited the
proliferation of oral tongue cancer cell lines HSC-3 and SCC25 [57]. Fermented juice
also inhibited the invasion of HSC-3, and similarly but not significantly that of SCC25.
Migration, however, was not inhibited in either cell line.
Table 3. Oral cancer. Main results of the cell study.



















500, 2500, 5000 ug/mL
48 h for proliferation
96 h for invasion
1. Significant inhibition at 2.5 and
5.0 mg/mL for both cell lines.
GI50 1162 µg/mL for HSC-3, GI50
773 µg/mL for SCC-25
2. Significantly reduced invasion
of HSC-3, invasion of SCC-25 was
similarly inhibited but result was
not significant
4. Discussion
The aim of this work was to systematically review all in vitro and in vivo English
written research publications related to the anticancer effects of lingonberry and bilberry on
digestive tract cancers. Published data was mainly focused on bilberry and CRC, and these
studies suggest antiproliferative and anti-tumor effect for various bilberry preparations.
Only one uncontrolled pilot human trial was identified, in which bilberry anthocyanin-rich
extract supplement modestly reduced cancer cells proliferation and increased apoptosis
compared to pre-intervention values in CRC tissue after treatment as short as 7 days [10].
Lingonberry preparations showed inhibitory effects comparable to bilberry in cell culture
models (Table 2), and freeze-dried lingonberry inhibited adenoma growth even more
than bilberry in the only animal experiment conducted on lingonberry [38]. Fermented
lingonberry juice inhibited the proliferation of oral carcinoma cells in vitro [57]. Taken
together, evidence from human trials is still needed, but all data to date from in vitro and
animal models support the antiproliferative and tumor-inhibitory effects of various bilberry
and lingonberry preparations on digestive tract cancers.
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In vitro, various bilberry extracts, even at low concentrations (GI50 values 25 µg/mL–
5 mg/mL) inhibited proliferation [39,41,43–45,47,50,51], and at higher concentrations
(above 20 mg/mL) induced apoptosis [41,44,49] in CRC cells. However, proanthocyanidin-
rich extracts of bilberry and lingonberry induced apoptosis already at far lower concentra-
tions, at the levels of micrograms/mL [55]. In vivo, the proliferation of CRC cells reduced
by nearly 50 % in rats with induced carcinogenesis, treated with bilberry anthocyanin
rich extract [34]. Small decrease in proliferation and increase in apoptotic index were also
detected in tumor tissue of bilberry-treated CRC patients [10]. The specific mechanism
behind the antiproliferative activity remains to be specified. Cell growth seems to be
inhibited in a cytostatic manner in cell culture [41,43,44,57], but apoptosis may be induced
after reaching a concentration threshold [44]. One animal study found that a reduction in
colonic cell proliferation in bilberry-treated rats was associated with reduced expression of
COX-2, suggesting a link with anti-inflammatory activity [34].
In the animal studies, bilberry extracts inhibited the formation of induced and ge-
netic murine intestinal malignant tumors, or pre-malignant transformations [9,34,35,38,39].
Interestingly, bilberry did not reduce the size of small-intestinal adenomas in contrast to
lingonberry [38]. In a later publication of this experiment, superior effect of cloudberry
compared to bilberry on adenoma size was found to be associated with downregulated
gene expression of energy metabolism-related genes and a smaller ratio of intraepithelial
to all mucosal CD3+ T lymphocytes in the intestinal mucosa [33]. Bilberry did not affect
the formation of subcutaneous tumors in a xenograft mouse model [36,37]. However, the
bilberry extract enhanced the effectivity of an immune checkpoint inhibitor drug against
subcutaneous tumors [36,37]. It is of note that tumors outside the digestive tract would
likely be exposed to lower concentrations of berry phytochemicals and their metabolites
than tumors in the digestive tract.
The studies we analyzed did not give an exact mechanistical explanation for antitumor
activity of lingonberry or bilberry. In the one human pilot study, both cellular proliferation
and apoptotic index in the tumor tissue were affected by bilberry extract supplementa-
tion [10]. According to the animal studies reviewed here, the anticancer effect of these
berries is suggested to come across, at least in part, via modulation of gut microbiota
and/or immune responses [33,35–37,39]. These effects could, to some extent, also impact
tumorigenesis outside the digestive tract [36,37]. In addition to local effects, systemic
effects could be reached via fluctuating postprandial pulses of phytochemicals, slow re-
lease of absorbable metabolites in the digestive tract, and accumulation to tissues during
prolonged exposure. Besides inhibiting the growth of tumors, berry extracts may inhibit
tumor initiation through their DNA-protecting abilities [11,53], supported by the lower
number of tumors or pre-cancerous transformations in animals treated with lingonberry
and bilberry extracts [9,34,35,38,39].
Anthocyanin-rich extracts are the most frequently examined berry extracts in digestive
tract cancers. However, based on our reviewed articles, the anticancer effect of some other
berry phytochemicals could be even stronger than that of anthocyanins [40,42,46], or the
activity may be synergistic between different compounds. Interestingly, freeze-dried lin-
gonberry reduced adenoma growth in the ApcMin/+ mouse model more than bilberry [38]
regardless of the lower anthocyanin content in lingonberry. Additionally, both lingonberry
and bilberry extracts inhibited CRC cell proliferation in vitro [41,44] regardless of their
differing phytochemical profiles [16]. In fact, the anthocyanin-rich fraction of lingonberry
extract was less antiproliferative than the whole lingonberry extract [32,33], or fractions
rich in proanthocyanins [33,34]. In addition, bilberry flavonol fraction and phenolic acid
fraction both inhibited proliferation of CRC cells, suggesting that antiproliferative activities
are shared by different phenolic compounds [51].
The relevance of in vitro studies with berry extracts is debatable, since berry phyto-
chemicals are extensively modified in the digestive tract, and preparations used in cell
culture differ in their chemical composure from the metabolites formed during digestion.
Therefore, in vitro studies with original berry extracts may have relevance in oral cavity
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cancers, but not necessarily in lower digestive tract neoplasia. Yet, based on effectivity
shown in vivo (Table 1), and the potency of different extracts in vitro (Tables 2 and 3),
anticancer effects on digestive tract cancers may not require high systemic bioavailability of
certain original berry phytochemicals. Some biological activity seems to persist even after
extensive modification by human and microbial enzymes [53,57]; however, more research
on this subject is needed.
The possible anticancer effects of lingonberry and bilberry are numerous, but exact
mechanisms and effective constituents are still unclear and yet to be investigated in cancer
prevention and treatment. Regardless of encouraging results from several in vitro and
animal studies on bilberry and CRC, only one pilot human trial has been conducted. Deeper
understanding of the effective lingonberry and bilberry components, their metabolites,
synergy, and underlying biological mechanisms is needed to pave the way for human
trials. Animal models have shown the potential of lingonberry and bilberry to inhibit
CRC carcinogenesis, but effective dose for humans cannot be deduced based on animal
studies. Proving preventive potential in human trials would require multicenter studies
with large populations and long follow-ups. Elaborating the anticancer mechanisms of
phytochemicals could reveal previously unseen or overlooked aspects of carcinogenesis,
and help not only to improve cancer treatment, but also to assess and minimize the cancer
risk of an individual. Possible therapeutic benefits of berry phytochemicals [36,37] and
potential undesired interactions [47] in combination treatments should also be carefully
investigated in future trials.
Due to varying methodology in reviewed studies, meta-analysis could not be con-
ducted. Reporting of experimental replicates and repeats was unclear in some in vitro
studies, and the statistical significance of the inhibition of cellular proliferation not always
tested, but we did not exclude any controlled studies based on reporting quality. In contrast
to our original inclusion criteria, one uncontrolled human pilot study was included, based
on the lack of controlled human studies. It should also be noted that many berries have
shown anticancer activities [11], but here we went through only research conducted on
lingonberry and bilberry, not entirely covering the research field of anticancer effects of
wild berries.
5. Conclusions
Based on the literature found, bilberry inhibits CRC cell proliferation and tumorigen-
esis in experimental models, but this effect has not yet been investigated in any placebo
controlled human trials. Data also suggested similar activity for lingonberry on CRC and
oral cancer cell lines. In addition to anthocyanins, various other berry phytochemicals
may have similar and synergistic inhibitory effects on tumor processes. The identification
of active berry components, exact local and systemic mechanisms of action, and effective
doses require further investigation.
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